
    
      This study is designed to evaluate the safety and efficacy of 4.8 g/day using 800 mg Asacol
      tablets as compared to 2.4g/day using 400 mg Asacol tablets in newly- and
      previously-diagnosed patients who are experiencing a flare-up of mildly to moderately active
      ulcerative colitis.
    
  